| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenues | 53,995 | - |
| Purchases of inventory | 8,443 | - |
| Other cost of sales | 1,047 | - |
| Gross profit | 44,505 | - |
| Sales and marketing | 41,200 | - |
| General and administrative | 20,283 | - |
| Research and development | 15,148 | - |
| Total operating expenses | 76,631 | - |
| Operating loss | -32,126 | - |
| Interest expense | 3,754 | - |
| Other (expense) income, net | -1,058 | - |
| Loss before income taxes | -36,938 | - |
| Income tax expense | 28 | - |
| Net loss | -36,966 | -23,779 |
| Fair value of common stock issued related to loan amendment | 2,152 | - |
| Change in fair value of long-term debt | 767 | -155 |
| Change in fair value of warrant liability | -1,572 | -1,532 |
| Depreciation and amortization | 1,647 | 1,073 |
| Stock-based compensation | 8,146 | 5,369 |
| Non-cash lease expense | 662 | 438 |
| Loss on fixed asset disposal | -590 | -343 |
| Loss on patent disposal | 11 | 6 |
| Remeasurement and foreign currency transaction loss | -17 | - |
| Excess and obsolete inventory related charges | -695 | -543 |
| Provision for credit losses | -17 | -6 |
| Amortization of premium of marketable securities | -224 | -193 |
| Non-cash changes in the fair value of nqdc plan | 1,069 | 1,097 |
| Trade and other receivables | 3,714 | 1,373 |
| Prepaids and other current assets | -257 | -375 |
| Inventory | 666 | 810 |
| Operating lease liability | -716 | -467 |
| Corporate-owned life insurance ('coli') asset | -406 | -406 |
| Other long-term assets | 529 | 294 |
| Accounts payable and accrued expenses | 1,762 | 901 |
| Accrued wages and fringe benefits | -4,656 | -2,510 |
| Current non-qualified deferred compensation liability | -1,739 | -1,709 |
| Other current liabilities | -111 | -403 |
| Non-qualified deferred compensation plan liability | 1,707 | 1,607 |
| Contract liabilities | -25 | -17 |
| Net cash used in operating activities | -25,757 | -20,538 |
| Purchase of marketable securities | 11,346 | 3,460 |
| Maturities of marketable securities | 25,500 | 22,000 |
| Purchase of plant and equipment | 1,679 | 745 |
| Patent filing fees | 34 | 13 |
| Net cash provided by investing activities | 12,441 | 17,782 |
| Proceeds from private placement of common stock | 14,792 | - |
| Issuance costs associated with private placement | 1,058 | - |
| Proceeds from exercise of stock options | 406 | 374 |
| Employee stock purchase plan ('espp') purchases | 548 | 548 |
| Net cash provided by financing activities | 14,688 | 922 |
| Net increase (decrease) in cash and cash equivalents | 1,372 | -1,834 |
| Cash and cash equivalents at beginning of period | 14,050 | - |
| Cash and cash equivalents at end of period | 15,422 | - |
AVITA Medical, Inc. (RCEL)
AVITA Medical, Inc. (RCEL)